Your first 90 days
Your first 90 days on VPRIV for Gaucher disease
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
VPRIV is a long-term schedule of IV infusions, one every other week, with a dose your doctor sets from your weight. On that schedule, the first 90 days hold 7 infusions. This page lays out that stretch from the FDA label, Takeda Patient Support and one insurer's written rules.
What has to happen before the first bottle ships
VPRIV has no REMS, so the first infusion waits on a confirmed diagnosis, a Start Form, an insurance approval and a healthcare setting ready for allergic reactions. These are the 7 things in the way, in order.
A confirmed diagnosis
The Cigna policy shown below asks for a blood or skin cell test showing low enzyme activity, or a genetic test showing changes in both copies of the GBA gene.Cigna policy
A dose from your doctor
For people new to enzyme therapy, the label's starting dose is 60 units/kg every other week.
- Your doctor can adjust it based on reaching and keeping your treatment goals.FDA label
If you are switching from imiglucerase
The label lets people on a stable imiglucerase dose start VPRIV at that same dose.
- The first VPRIV infusion comes 2 weeks after the last imiglucerase infusion.FDA label
Your current weight
The dose is counted in units per kilogram.
- The label says the number of vials to mix is based on your weight and the prescribed dose.FDA label
The Start Form
You and your doctor complete the VPRIV Start Form, and you sign the Patient Authorization section.
- Takeda Patient Support then confirms your eligibility, and a support specialist calls you.VPRIV support programs page
Where the first infusion will happen
Takeda says infusions take place at an infusion center at first, under the supervision of a healthcare professional.
- The label requires a healthcare setting with emergency equipment for the start.VPRIV infusion page
The insurance check and QuickStart
A prior authorization can delay the start of treatment.
- Takeda's QuickStart program lets eligible people receive up to 2 free doses of VPRIV while the insurer reviews it.VPRIV support programs page
The days that matter
Counted from the first infusion, on the label's every other week schedule. Your doctor can adjust the dose over time, based on your treatment goals. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.The Start Form and the insurance check
Your doctor sends the Start Form, and Takeda Patient Support checks your insurance benefits.
- No source sets how long this takes, because each insurer works on its own timeline.
Prior authorization, or QuickStart
If your plan requires a prior authorization, QuickStart may supply up to 2 doses at no charge during the review.
- It does not cover dosing and administration costs, and Medicare and Medicaid prescriptions are excluded.
First infusion
A healthcare provider who knows how to manage severe allergic reactions supervises the infusion, in a healthcare setting with emergency equipment.
- The infusion runs over 60 minutes through a filter in the IV line.
Infusion 2, two weeks later
If you had allergy symptoms with an earlier VPRIV infusion, the label says to consider allergy medicines or steroids beforehand.
- In the trials, people were not routinely given these medicines before infusions.
Infusion 3
Takeda says the infusion is scheduled for 60 minutes, and you may need to stay longer for monitoring afterward.
- At first, infusions take place at an infusion center.
Infusion 4
Takeda Patient Support coordinates between your specialty pharmacy and your site of care.
- Its PreppedAhead program lets enrolled sites prepare the medicine before you arrive, so you wait less.
Infusion 5
If your infusions are well tolerated, Takeda says you may eventually be able to arrange home infusions with your doctor.
- A healthcare professional would come to your home to give them.
Infusion 6
In the trials, allergic reactions in people new to enzyme therapy mostly began in the first 6 months.
- The label says they were generally mild and tended to happen less often with time.
Infusion 7
This is the seventh infusion counted from day 1.
- In the label's trials of people new to treatment, hemoglobin was measured at 9 months and 12 months, well past this point.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current VPRIV label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated November 26, 2024, read from the FDA's label database today. FDA label
- November 2024
DailyMed posted version 27 of the label, with the prescribing information marked revised September 2024. Its recent changes list still dates the last major changes to July 2024.FDA label
- July 2024
The FDA added a boxed warning for severe allergic reactions, including anaphylaxis, as part of a change for enzyme replacement therapies as a group. VPRIV must now be started in a healthcare setting with emergency equipment.FDA letter
- December 2020
The FDA approved a 0.22 micron filter as an option for the IV line. It also added new antibody findings from an extension study and updated the breastfeeding wording.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- The starting dose
For adults and children 4 years and older who are new to enzyme therapy, the label's starting dose is 60 units/kg.
- It is given every other week.FDA label
- Dose changes
The label lets your doctor adjust the dose based on reaching and keeping your treatment goals.
- Doses above 60 units/kg were not studied in the trials.FDA label
- Switching from imiglucerase
Adults and children 4 years and older on a stable imiglucerase dose may start VPRIV at that same dose.
- VPRIV starts 2 weeks after the last imiglucerase infusion.FDA label
- How the dose is mixed
Each vial holds 400 units of powder, mixed with sterile water and then added to 100mL of salt water.
- The number of vials depends on your weight and your dose.FDA label
- Infusion time
Each infusion runs over 60 minutes through a filter in the IV line.
- The label says not to give VPRIV in the same tubing as other products.FDA label
- Medicines before an infusion
The label says to consider antihistamines or steroids before infusions for people who had allergy symptoms with earlier VPRIV infusions.
- Your doctor decides what you or your child gets.FDA label
- If a reaction happens
Depending on how severe it is, staff may slow the infusion, give allergy, fever or steroid medicines, or stop and restart it over a longer time.
- For a severe reaction, the label says to stop VPRIV and treat at once.FDA label
- If an infusion is missed
The label gives no missed-dose instructions.
- Takeda Patient Support says it can coordinate your specialty pharmacy and site of care when you travel or relocate.VPRIV support programs page
- Children
The label covers children 4 to 17 years old with type 1 Gaucher disease.
- Safety and effectiveness have not been established in children younger than 4.FDA label
- Pregnancy
Data on more than 300 pregnancies have not shown a link between VPRIV and birth defects, miscarriage or other harm.
- The label adds that these data cannot fully rule out a risk, and that pregnancy can make Gaucher disease worse.FDA label
- Breastfeeding
No data show whether VPRIV passes into breast milk.
- The label says to weigh the benefits of breastfeeding against the mother's need for VPRIV and any possible effects on the child.FDA label
- Older adults
The label says dose selection for an older person should be approached with caution, considering other health conditions.
- Side effects in older people matched those seen in others.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Signs of a severe allergic reaction
Takeda's safety information lists wheezing, shortness of breath, trouble breathing, itching, hives, a rapid heartbeat, and swelling of the tongue or throat.
- It says to seek immediate help if these happen.VPRIV safety information
Anaphylaxis can come late in treatment
The boxed warning says anaphylaxis has happened early in enzyme replacement therapy and after long use.
- If it happens, the label says to stop VPRIV and treat it at once, including with epinephrine.FDA label
Common allergic reaction symptoms
Headache, dizziness, low blood pressure, high blood pressure, nausea, tiredness or weakness, and fever were the most common in the trials.
- Chest discomfort, trouble breathing, itching and vomiting were reported after approval.FDA label
How common reactions were
In the trials, 52% of people new to enzyme therapy had an allergic reaction, as did 23% of those who switched from imiglucerase.
- These counted any related event within 24 hours of an infusion, including one case of anaphylaxis.FDA label
Other side effects
The label lists headache, dizziness, fever, belly pain, back pain, knee pain, tiredness, nausea and a longer blood clotting test time.
- Vomiting has in some cases been serious, needing a hospital stay or stopping the drug.FDA label
Antibodies
In the trials, 1 of 54 people new to enzyme therapy formed antibodies to VPRIV, and one more did in an extension study.
- The antibodies were not linked to allergic reactions.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedThe Cigna policy below asks for a lab report showing low enzyme activity in white blood cells or skin cells, or a genetic test showing changes in both GBA genes.Cigna policy
- The review is taking too longQuickStart may provide up to 2 doses at no charge while a prior authorization is being reviewed. It is not valid for prescriptions covered by Medicaid, Medicare or similar programs.VPRIV Start Form
- The patient is younger than 4Cigna requires age 4 or older. The label says safety and effectiveness have not been established in children younger than 4.Cigna policy
- The doctor is not a specialistCigna asks that VPRIV be prescribed by, or with advice from, a geneticist, endocrinologist, metabolic specialist or lysosomal storage disorder specialist.Cigna policy
- The request mentions brain or nerve symptomsCigna does not cover VPRIV to manage neurological symptoms such as seizures or abnormal eye movement.Cigna policy
- Also taking another Gaucher medicineCigna treats VPRIV used together with Cerdelga, Elelyso, Cerezyme or Zavesca as not medically necessary. Your doctor decides which treatment fits you.Cigna policy
- A dose above the plan's limitCigna allows up to 60 units/kg per dose, no more often than once every 2 weeks. A clinician at the plan reviews other doses case by case.Cigna policy
- A copay you cannot payCommercial insurance: the Takeda Patient Support Co-Pay Assistance Program may cover up to 100% of out-of-pocket copay costs, up to a program maximum. Medicare, Medicare Advantage, Medicaid, TRICARE and other government coverage are excluded.VPRIV support programs for HCPs
- Your plan uses a copay maximizerTakeda's terms say it may reduce or end copay help for people whose plan uses a copay maximizer program. The terms ask you to call 1-866-888-0660 if you learn your plan has one.VPRIV support programs for HCPs
- Your insurance changesThe copay program's terms say you must tell the program right away, at 1-866-888-0660. Takeda Patient Support also lists help with insurance changes among its services.VPRIV support programs for HCPs
Cigna prior authorization policy, June 15, 2026
- Gaucher disease type 1, in someone 4 years of age or older
- One documented test showing low beta-glucocerebrosidase activity in white blood cells or skin cells, or disease-causing variants in both GBA genes
- Not used to manage neurological symptoms, such as abnormal eye movement, hearing loss, thinking problems or seizures
- Prescribed by, or with advice from, a geneticist, endocrinologist, metabolic disorder specialist or lysosomal storage disorder specialist
- Each dose no more than 60 units/kg by IV, no more often than once every 2 weeks
- Not used together with Cerdelga, Elelyso, Cerezyme or Zavesca
Approval length. One year.
This policy (Drug Coverage Policy IP0164) took effect June 15, 2026 and cites the September 2024 VPRIV label, the current one. Under a heading for other uses with supportive evidence, it also covers VPRIV for type 3 Gaucher disease on the same terms. That use is outside the FDA label, which covers type 1 only. It is here as an example of what a plan asks for, not as a rule. Cigna policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- A support specialist for your questions, with phone help in other languages, including Spanish and Yiddish, through a translation service
- Copay assistance for eligible people with commercial insurance, plus help with reimbursement and insurance issues
- The Co-Pay Assistance Program may cover up to 100% of out-of-pocket copay costs, up to a program maximum, with no financial requirements or waiting periods VPRIV support programs for HCPs
- Copay help cannot be used with Medicare, Medicare Advantage, Medicaid, TRICARE or other government-funded coverage, under the program's terms VPRIV support programs for HCPs
- QuickStart, up to 2 free doses of VPRIV for eligible people while a prior authorization is reviewed
- Coordination between your specialty pharmacy and your site of care, including when you travel or relocate
- PreppedAhead, which lets enrolled sites of care prepare the infusion before you arrive
- Help during life changes such as relocation, moving to college or changing jobs
Details as the drugmaker publishes them. VPRIV support programs page
Five questions for the pharmacist or the support line
- Who orders my VPRIV for each infusion, and where is it shipped?
- Is my dose based on my current weight, and who do I tell if my weight changes?
- How many vials make up my dose?
- Will I get any medicine before my infusion, and why or why not?
- How long will I be monitored after each infusion?
- Is my site of care enrolled in PreppedAhead?
- If I move to home infusion, who brings the medicine and who gives it?
Questions people ask in the first weeks
How long does a VPRIV infusion take?
The label sets 60 minutes for each infusion. Takeda says you may need to stay longer for monitoring afterward, and that the site of care needs time to prepare the medicine.
How often will I get VPRIV?
Every other week, according to the label. The starting dose for people new to enzyme therapy is 60 units/kg, and your doctor can adjust it over time.
Can I get VPRIV at home?
Not at first. The label says to start VPRIV in a healthcare setting with emergency equipment, and it does not mention home infusion. Takeda says that if infusions are well tolerated, you may eventually arrange home infusions with your doctor.
Will I get medicine before my infusion?
Only if your doctor decides you need it. The label says to consider antihistamines or steroids for people who had allergy symptoms with earlier VPRIV infusions. People in the trials were not routinely given them.
Does VPRIV have a boxed warning?
Yes. Since July 2024 the label has carried a boxed warning for severe allergic reactions, including anaphylaxis. The FDA asked for this warning on enzyme replacement therapies as a group.
Can children receive VPRIV?
The label covers children 4 years and older with type 1 Gaucher disease. Safety and effectiveness have not been established in children younger than 4.
Can I switch from Cerezyme to VPRIV?
The label describes how. People on a stable dose of imiglucerase, the drug in Cerezyme, may start VPRIV at that same dose 2 weeks after their last imiglucerase infusion. Your doctor decides whether a switch fits you.
Does VPRIV treat type 3 Gaucher disease?
The FDA label covers type 1 Gaucher disease only. The Cigna policy shown here also covers VPRIV for type 3, though not to manage brain or nerve symptoms. That is one insurer's coverage rule for a use outside the FDA label, not an FDA approval.
How long does it take to start VPRIV after it is prescribed?
There is no fixed number of days. The Start Form, the insurance check, prior authorization and booking an infusion site each take their own time. QuickStart may provide up to 2 free doses for eligible people during the review.
Free email alert
Hear when the VPRIV label changes
One email the day the FDA revises the VPRIV label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for VPRIV only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Gaucher disease for new trials, FDA decisions and label changes for every treatment.
Sources
- DailyMed - VPRIV- velaglucerase alfa injection, powder, lyophilized, for solution (updated November 26, 2024, SPL version 27, prescribing information revised 9/2024), Takeda Pharmaceuticals America, Inc., via DailyMed, November 26, 2024.
- VPRIV® Support Programs | VPRIV® (velaglucerase alfa) for injection, Takeda, May 1, 2025.
- Your VPRIV® Infusion | VPRIV® (velaglucerase alfa) for injection, Takeda, May 1, 2025.
- VPRIV® (velaglucerase alfa for injection) | Enzyme Replacement Therapy, Takeda, March 1, 2026.
- Takeda Support Programs | VPRIV® (velaglucerase alfa) for injection, Takeda, September 1, 2025.
- VPRIV® (velaglucerase alfa) Patient Start Form (US-VEL-0616v1.0 08/24), Takeda, August 1, 2024.
- Gaucher Disease – Enzyme Replacement Therapy – Vpriv, Drug Coverage Policy IP0164, Cigna, June 15, 2026.
- BLA 022575/S-030 supplement approval letter, enzyme replacement therapy class safety labeling change for hypersensitivity, FDA, July 10, 2024.
- BLA 022575/S-026 supplement approval letter, 0.22 micron filter, immunogenicity and lactation updates, FDA, December 10, 2020.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing geneticist. Found an error? Use the report link in the footer and it will be checked against the source.